Z 338 clinical trials
Also written Z-338, Acotiamide and YM443.
How each study uses Z 338 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Z 338 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2014 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 2
Zeria Pharmaceutical (7) · Astellas Pharma Inc (4) · Universitaire Ziekenhuizen KU Leuven (1) · Aga Khan University (1) · Getz Pharma (1)
Related medicines
As reviewed, each with the page that says it.
- One of Cholinesterase inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test Z 338, phase 3 first.
- Dec 2026Acotiamide vs Itopride in Postprandial Distress SyndromePhase 3 · Getz Pharma
- Dec 2026Comparing Acotiamide and Itopride for the Management of IndigestionPhase 4 · Aga Khan University
Studies
Open first, then newest update. How each study uses Z 338 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Comparing Acotiamide and Itopride for the Management of IndigestionNot yet recruitingPhase 4Aga Khan UniversityNCT07449689Written as Acotiamide
- Acotiamide vs Itopride in Postprandial Distress SyndromeNot yet recruitingPhase 3Getz PharmaNCT07174297Written as Acotiamide
- A Phase III Trial of Z-338 in Paediatric Patients With Functional DyspepsiaCompletedPhase 3Zeria PharmaceuticalNCT04526119Written as Acotiamide hydrochloride hydrate
- Effect of Acotiamide on Gastric Motility and Satiation in Healthy VolunteersCompletedNot applicableUniversitaire Ziekenhuizen KU LeuvenNCT03402984Written as Acotiamide
- YM443 in Subjects With Functional DyspepsiaCompletedPhase 2Astellas Pharma IncNCT00102310Written as YM443
- Phase III, Long-term, Open-label Safety Study of Z-338CompletedPhase 3Zeria PharmaceuticalNCT01973790Written as Z-338
- To Evaluate the Efficacy and Safety in Subjects With Functional DyspepsiaCompletedPhase 2Zeria PharmaceuticalNCT00323817Written as Z-338
- A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional DyspepsiaCompletedPhase 3Astellas Pharma IncNCT00764374Written as YM443
- A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy AdultsCompletedPhase 1Astellas Pharma IncNCT00850746Written as YM443
- To Verify the Efficacy of Z-338 in Subjects With Functional DyspepsiaCompletedPhase 3Zeria PharmaceuticalNCT00761358Written as Z-338
- The Effect of Z-338 in Subjects With Functional DyspepsiaCompletedPhase 2Zeria PharmaceuticalNCT00458328Written as Z-338
- Effect of Food Intake on Pharmacokinetic Profiles of Z-338CompletedPhase 1Astellas Pharma IncNCT00920998Written as Z-338
- The Effects of Z-338 in Subjects With and Without Functional DyspepsiaCompletedPhase 2Zeria PharmaceuticalNCT00298194Written as Z-338
- To Evaluate the Efficacy of Z-338 in Subjects With Functional DyspepsiaCompletedPhase 2Zeria PharmaceuticalNCT00333372Written as Z-338
As the comparator · 1 — what is tested is compared with Z 338
Codes
What other systems call Z 338 · ClinicalTrials.gg INT004252
- MeSH (NLM) C410959Z 338Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) D42OWK5383ACOTIAMIDEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C410959 | Z 338 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | D42OWK5383 | ACOTIAMIDE | Confirmed FDA, NLM |
Also registered as acotiamide hydrochloride (UNII NMW7447A9A).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.